CGRP receptor antagonists: design and screening

David R. Poyner, Debbie L. Hay, Alex C. Conner

Research output: Contribution to journalReview article

Abstract

Importance of the field: Calcitonin gene-related peptide (CGRP) receptor antagonists have recently come to attention with the development of olcegepant and telcagepant for the treatment of migraine. The availability of high-affinity, non-peptide antagonists opens the way for trials of these compounds in other conditions where CGRP antagonism might be useful, such as septic shock and inhibition of angiogenesis. Areas covered in this review: This review summarises knowledge about the structure and signalling properties of the CGRP receptor. The clinical ramifications of targeting the CGRP receptor, the profiles of existing antagonists and the requirements for screening new compounds will be discussed. What the reader will gain: Readers will gain an overview of how current non-peptide antagonists seem to bind similar epitopes contributed by both calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1), the main CGRP receptor subunits. We will discuss how current antagonists have low bioavailability, limiting their use. For selectivity at CGRP receptors, it will be necessary to target parts of the receptor influenced by both RAMP1 and CLR. Take home message: For the design of radically new antagonists, more structural information on the receptor is needed. Current screens are largely based on measuring CGRP-mediated changes in cAMP. CGRP receptors can influence other signalling pathways and pathway-selective allosteric antagonists may be useful, but more information is needed about the mechanism of action of CGRP to assess the value of this.

LanguageEnglish
Pages1253-1265
Number of pages13
JournalExpert Opinion on Drug Discovery
Volume4
Issue number12
Early online date24 Nov 2009
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Calcitonin Gene-Related Peptide Receptors
Calcitonin Gene-Related Peptide
Receptor Activity-Modifying Protein 1
Calcitonin Receptor-Like Protein
Septic Shock
Migraine Disorders
Biological Availability
Epitopes

Keywords

  • cell signalling
  • G-protein-coupled receptor
  • migraine
  • modelling

Cite this

Poyner, David R. ; Hay, Debbie L. ; Conner, Alex C. / CGRP receptor antagonists : design and screening. In: Expert Opinion on Drug Discovery. 2009 ; Vol. 4, No. 12. pp. 1253-1265.
@article{1ce86a9c5e6c42d9a56d9b6c81d0cd56,
title = "CGRP receptor antagonists: design and screening",
abstract = "Importance of the field: Calcitonin gene-related peptide (CGRP) receptor antagonists have recently come to attention with the development of olcegepant and telcagepant for the treatment of migraine. The availability of high-affinity, non-peptide antagonists opens the way for trials of these compounds in other conditions where CGRP antagonism might be useful, such as septic shock and inhibition of angiogenesis. Areas covered in this review: This review summarises knowledge about the structure and signalling properties of the CGRP receptor. The clinical ramifications of targeting the CGRP receptor, the profiles of existing antagonists and the requirements for screening new compounds will be discussed. What the reader will gain: Readers will gain an overview of how current non-peptide antagonists seem to bind similar epitopes contributed by both calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1), the main CGRP receptor subunits. We will discuss how current antagonists have low bioavailability, limiting their use. For selectivity at CGRP receptors, it will be necessary to target parts of the receptor influenced by both RAMP1 and CLR. Take home message: For the design of radically new antagonists, more structural information on the receptor is needed. Current screens are largely based on measuring CGRP-mediated changes in cAMP. CGRP receptors can influence other signalling pathways and pathway-selective allosteric antagonists may be useful, but more information is needed about the mechanism of action of CGRP to assess the value of this.",
keywords = "cell signalling, G-protein-coupled receptor, migraine, modelling",
author = "Poyner, {David R.} and Hay, {Debbie L.} and Conner, {Alex C.}",
year = "2009",
month = "12",
doi = "10.1517/17460440903413496",
language = "English",
volume = "4",
pages = "1253--1265",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "12",

}

CGRP receptor antagonists : design and screening. / Poyner, David R.; Hay, Debbie L.; Conner, Alex C.

In: Expert Opinion on Drug Discovery, Vol. 4, No. 12, 12.2009, p. 1253-1265.

Research output: Contribution to journalReview article

TY - JOUR

T1 - CGRP receptor antagonists

T2 - Expert Opinion on Drug Discovery

AU - Poyner, David R.

AU - Hay, Debbie L.

AU - Conner, Alex C.

PY - 2009/12

Y1 - 2009/12

N2 - Importance of the field: Calcitonin gene-related peptide (CGRP) receptor antagonists have recently come to attention with the development of olcegepant and telcagepant for the treatment of migraine. The availability of high-affinity, non-peptide antagonists opens the way for trials of these compounds in other conditions where CGRP antagonism might be useful, such as septic shock and inhibition of angiogenesis. Areas covered in this review: This review summarises knowledge about the structure and signalling properties of the CGRP receptor. The clinical ramifications of targeting the CGRP receptor, the profiles of existing antagonists and the requirements for screening new compounds will be discussed. What the reader will gain: Readers will gain an overview of how current non-peptide antagonists seem to bind similar epitopes contributed by both calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1), the main CGRP receptor subunits. We will discuss how current antagonists have low bioavailability, limiting their use. For selectivity at CGRP receptors, it will be necessary to target parts of the receptor influenced by both RAMP1 and CLR. Take home message: For the design of radically new antagonists, more structural information on the receptor is needed. Current screens are largely based on measuring CGRP-mediated changes in cAMP. CGRP receptors can influence other signalling pathways and pathway-selective allosteric antagonists may be useful, but more information is needed about the mechanism of action of CGRP to assess the value of this.

AB - Importance of the field: Calcitonin gene-related peptide (CGRP) receptor antagonists have recently come to attention with the development of olcegepant and telcagepant for the treatment of migraine. The availability of high-affinity, non-peptide antagonists opens the way for trials of these compounds in other conditions where CGRP antagonism might be useful, such as septic shock and inhibition of angiogenesis. Areas covered in this review: This review summarises knowledge about the structure and signalling properties of the CGRP receptor. The clinical ramifications of targeting the CGRP receptor, the profiles of existing antagonists and the requirements for screening new compounds will be discussed. What the reader will gain: Readers will gain an overview of how current non-peptide antagonists seem to bind similar epitopes contributed by both calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1), the main CGRP receptor subunits. We will discuss how current antagonists have low bioavailability, limiting their use. For selectivity at CGRP receptors, it will be necessary to target parts of the receptor influenced by both RAMP1 and CLR. Take home message: For the design of radically new antagonists, more structural information on the receptor is needed. Current screens are largely based on measuring CGRP-mediated changes in cAMP. CGRP receptors can influence other signalling pathways and pathway-selective allosteric antagonists may be useful, but more information is needed about the mechanism of action of CGRP to assess the value of this.

KW - cell signalling

KW - G-protein-coupled receptor

KW - migraine

KW - modelling

UR - http://www.tandfonline.com/10.1517/17460440903413496

UR - http://www.scopus.com/inward/record.url?scp=73549086745&partnerID=8YFLogxK

U2 - 10.1517/17460440903413496

DO - 10.1517/17460440903413496

M3 - Review article

VL - 4

SP - 1253

EP - 1265

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 12

ER -